Amarantus BioSciences, Inc. Reports Positive MANF Data in Neuroprotection Animal Models of Parkinson's Disease
3/27/2013 11:03:50 AM
SUNNYVALE, Calif.--(BUSINESS WIRE)--Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today reported positive preclinical data for its lead therapeutic MANF in neuroprotection 6-hydroxydopamine (6-OHDA) rat models of Parkinson’s disease. The data show that MANF protects the integrity of dopamine producing neurites in the striatum.
comments powered by